Sabra Health Care REIT, Inc. (FRA:SBC)
Germany · Delayed Price · Currency is EUR | Market Cap | 4.41B +20.4% |
| Revenue (ttm) | 756.06M +17.7% |
| Net Income | 57.28M -64.1% |
| EPS | 0.23 -65.6% |
| Shares Out | n/a |
| PE Ratio | 76.93 |
| Forward PE | 25.90 |
| Dividend | 1.03 (6.20%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 250 |
| Open | 16.58 |
| Previous Close | 17.00 |
| Day's Range | 16.58 - 16.58 |
| 52-Week Range | 14.74 - 19.56 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 4, 2026 |
About Sabra Health Care REIT
Sabra Health Care REIT, Inc. operates as a self-administered, self-managed real estate investment trust that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada. Sabra Health Care REIT, Inc. is incorporated on May 10th, 2010 and is based in Tustin, United States. [Read more]
Financial Performance
In 2025, Sabra Health Care REIT's revenue was $775.76 million, an increase of 10.41% compared to the previous year's $702.64 million. Earnings were $155.61 million, an increase of 22.81%.
Financial numbers in USD Financial StatementsNews
Sabra Health Care price target lowered to $20 from $21 at UBS
UBS analyst Michael Goldsmith lowered the firm’s price target on Sabra Health Care (SBRA) to $20 from $21 and keeps a Neutral rating on the shares.
Sabra Health Care price target lowered to $21 from $23 at Barclays
Barclays analyst Richard Hightower lowered the firm’s price target on Sabra Health Care (SBRA) to $21 from $23 and keeps an Equal Weight rating on the shares. The firm adjusted…
Sabra Health Care initiated with an Outperform at Huntington
Huntington initiated coverage of Sabra Health Care (SBRA) with an Outperform rating and $23 price target Sabra can deliver solid earnings growth through improving core skilled nursing facility fundame...
Sabra Health Care initiated with an Outperform at Huntington
Huntington initiated coverage of Sabra Health Care (SBRA) with an Outperform rating and $23 price target
Sabra Health Care REIT, Inc., Issues Business Update and will Participate in the BofA Securities 2026 Global Real Estate Conference
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #SBRA--In conjunction with upcoming investor meetings, Sabra Health Care REIT, Inc. (Nasdaq: SBRA) has issued a business update, which is available on the com...
Sabra Health Care REIT Slides: Investor presentation
Sabra Health Care REIT has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Sabra Health Care price target raised to $21 from $20 at Mizuho
Mizuho raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps a Neutral rating on the shares.
Sabra Health Care price target raised to $23 from $21 at Barclays
Barclays analyst Richard Hightower raised the firm’s price target on Sabra Health Care (SBRA) to $23 from $21 and keeps an Equal Weight rating on the shares. The firm adjusted…
Sabra Health Care upgraded to Market Perform from Underperform at Raymond James
Raymond James analyst David Rodgers upgraded Sabra Health Care (SBRA) to Market Perform from Underperform without a price target The company’s preannounced tenant and operator transitions “offered a s...
Sabra Health Care REIT Earnings Call Transcript: Q2 2026
Second quarter results showed strong sequential and year-over-year growth in managed senior housing, with robust investment activity and a healthy pipeline. Leverage improved to 4.61x, and 2026 guidance was reaffirmed, projecting 7–8% normalized FFO/AFFO growth.
Sabra Health Care REIT Earnings release: Q2 2026
Sabra Health Care REIT released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Sabra Health Care REIT Quarterly report: Q2 2026
Sabra Health Care REIT has published its Q2 2026 quarterly earnings report on August 4, 2026.
Sabra Health Care REIT Slides: Q2 2026
Sabra Health Care REIT has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Sabra Reports Second Quarter 2026 Results; Reiterates 2026 Guidance
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #2Q26--Sabra Health Care REIT, Inc. (“Sabra,” the “Company” or “we”) (Nasdaq: SBRA) today announced its results of operations for the second quarter of 2026. ...
Sabra Health Care REIT, Inc., Publishes Sixth Annual Sustainability Report
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #ESG--Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) (Nasdaq: SBRA) today released its sixth annual Sustainability Report for fiscal year 2025.The re...
Sabra Health Care price target raised to $25 from $22 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Sabra Health Care (SBRA) to $25 from $22 and keeps a Buy rating on the shares. The company’s business update shows its…
Sabra Health Care price target raised to $23 from $22 at Baird
Baird analyst Wesley Golladay raised the firm’s price target on Sabra Health Care (SBRA) to $23 from $22 and keeps a Neutral rating on the shares.The firm updated its model…
Sabra Health Care price target raised to $25 from $23 at Citizens
Citizens analyst Aaron Hecht raised the firm’s price target on Sabra Health Care (SBRA) to $25 from $23 and keeps an Outperform rating on the shares. Sabra Health Care raised…
Sabra Issues Business Update and Increases Full-Year 2026 Guidance
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #GUIDANCE--Sabra Health Care REIT, Inc. (“Sabra,” the “Company” or “we”) (Nasdaq: SBRA) today announced a business update detailed below. Portfolio Update Sab...
Sabra Health Care REIT, Inc. Announces Second Quarter 2026 Earnings Release Date and Conference Call
TUSTIN, Calif.--(BUSINESS WIRE)---- $SBRA #2Q26--Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that it will issue its 2026 second quarter earnings release on August 3, 2026, after the cl...
Sabra Health Care price target lowered to $21 from $22 at UBS
UBS lowered the firm’s price target on Sabra Health Care (SBRA) to $21 from $22 and keeps a Neutral rating on the shares.
Sabra Health Care upgraded to Buy from Hold at Truist
Truist upgraded Sabra Health Care (SBRA) to Buy from Hold with an unchanged $22 price target as part of a broader research note on REITs. The firm is positive on…
Sabra Health Care initiated with an Equal Weight at Barclays
Barclays initiated coverage of Sabra Health Care (SBRA) with an Equal Weight rating and $21 price target While initiating coverage of six healthcare REITs, the analyst tells investors that healthcare…
Sabra Health Care downgraded to Neutral from Buy at Citi
Citi downgraded Sabra Health Care (SBRA) to Neutral from Buy with a price target of $19, down from $24. The firm believes Sabra’s earnings accretion from acquisitions is increasingly weighed…
Sabra Health Care price target lowered to $19 from $22 at Scotiabank
Scotiabank lowered the firm’s price target on Sabra Health Care (SBRA) to $19 from $22 and keeps a Sector Perform rating on the shares. The firm sees real estate investment…